封面
市場調查報告書
商品編碼
2076261

單株抗體療法市場:按原料、應用、分銷管道和地區分類

Monoclonal Antibody Therapeutics Market, By Source, By Application, By Distribution Channel, And by Region

出版日期: | 出版商: Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2026 年,單株抗體療法市場規模將達到 3,096.578 億美元,到 2033 年將達到 8,137.206 億美元。預計 2026 年至 2033 年的複合年成長率將達到 14.8%。

報告範圍 報告詳情
基準年: 2025 2026年市場規模: 3096.578億美元
歷史數據時期: 2020-2024 預測期: 2026-2033
2026年至2033年預測期間的複合年成長率: 14.80% 2033年市場規模預測: 8137.206億美元

免疫系統由複雜的機制構成,能夠辨識並摧毀細菌和病毒等病原體。同樣,該系統也能清除癌細胞等受損細胞。免疫系統發現並摧毀入侵者的一種方式是透過抗體的作用。單株抗體療法是一種免疫療法,它使用能夠特異性結合特定細胞或蛋白質的單株抗體(mAbs)。此療法的目標是刺激患者的免疫系統攻擊這些細胞。近年來,多種作用機制獨特的單株抗體已獲批准上市,這些抗體可作用於CTLA-4、PD-1和PD-L1等免疫查核點。製藥公司正致力於開發各類藥物,以治療從癌症到罕見疾病等多種疾病。單株抗體與化療藥物合併使用正成為治療多種癌症的有效選擇。 2020年,用於治療COVID-19的單株抗體療法的研發也加速推進。

市場動態

預計在預測期內,採用包括獲得市場主要監管機構批准在內的成長策略來拓展產品系列將推動市場成長。例如,2022年2月,美國食品藥物管理局(FDA)授予禮來製藥公司生產的新型單株抗體bebuterobimab緊急使用授權(EUA),用於治療COVID-19,該藥物對omicron變異株也有效。

本研究的主要特點:

  • 本研究揭示了各個細分市場的潛在商機,並為該市場說明了一個具有吸引力的投資提案矩陣。
  • 此外,本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
  • 本研究根據以下參數介紹了全球單株抗體治療市場主要公司的概況:公司概況、產品系列、主要亮點、財務表現和策略。
  • 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
  • 這份《全球單株抗體療法市場》報告針對產業內的各種相關人員,包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過分析全球單株抗體療法市場中使用的各種策略矩陣來促進決策。

目錄

第1章:研究目標與前提條件

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • 一致性機會圖(COM)

第3章:市場動態、監管與趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 影響分析
  • 產品發布
  • 技術進步
  • PEST分析
  • 監管趨勢
  • 併購

第4章:全球單株抗體療法市場:依來源分類

  • 人類來源
  • 嵌合體體
  • 小鼠來源
  • 人性化

第5章 全球單株抗體療法市場:依應用領域分類,2021-2033年

  • 癌症
  • 自體免疫疾病
  • 血液疾病
  • 感染疾病
  • 其他

第6章 全球單株抗體療法市場:依通路分類,2021-2033年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 全球單株抗體療法市場:依地區分類,2021-2033年

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲國家
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 澳洲
    • 韓國
    • 其他亞太國家
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 北非
    • 中非
    • 南非

第8章 競爭情勢

  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Merck KGaA
  • GSK plc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca
  • AbCellera Biologics Inc.
  • Molecular Depot LLC
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Abbott
  • Biogen
  • Thermo Fisher Scientific, Inc.
  • Cell Signaling Technology, Inc
  • Intas Pharmaceuticals Ltd.
  • Avantor, Inc.
  • UCB SA
  • Merus NV
  • GENEXTGENOMICS.COM
  • Biogenuix

第9章

  • 調查方法
  • 關於本公司
簡介目錄
Product Code: CMI5612

Monoclonal Antibody Therapeutics Market is estimated to be valued at USD 3,09,657.8 Mn in 2026 and is expected to reach USD 8,13,720.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 14.8% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 3,09,657.8 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 14.80% 2033 Value Projection: USD 8,13,720.6 Mn

The immune system is made up of a complex team of players that detect and destroy disease-causing agents, such as bacteria and viruses. Similarly, this system may eliminate damaged cells, such as cancer cells. One way the immune system finds and destroys invaders is with antibodies. Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patient's immune system to attack those cells. Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. Also, there was a boost in the development of monoclonal antibody therapeutics for the treatment of COVID-19 in the year 2020

Market Dynamics

Increasing adoption of growth strategies, such as authorization by key regulatory authorities in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in February 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a new monoclonal antibody, bebtelovimab manufactured by Lilly, a pharmaceutical company for the treatment of COVID-19 that retains activity against the omicron variant.

Key features of the study:

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global monoclonal antibody therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck KGaA, GSK plc., AbbVie Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., AstraZeneca, AbCellera Biologics Inc., Molecular Depot LLC, DAIICHI SANKYO COMPANY, LIMITED., Abbott, Biogen, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc, Intas Pharmaceuticals Ltd., Avantor Inc., UCB S.A., Merus N.V., GENEXTGENOMICS.COM, Biogenuix
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global monoclonal antibody therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibody therapeutics market

Detailed Segmentation:

  • Global Monoclonal Antibody Therapeutics Market, By Source (Revenue, USD Mn, 2021 - 2033)
  • Human
  • Chimeric
  • Murine
  • Humanized
  • Global Monoclonal Antibody Therapeutics Market, By Application (Revenue, USD Mn, 2021 - 2033)
  • Cancer
  • Autoimmune Disease
  • Hematological Disease
  • Infectious Disease
  • Others
  • Global Monoclonal Antibody Therapeutics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global Monoclonal Antibody Therapeutics Market, By Region (Revenue, USD Mn, 2021 - 2033)
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
  • Pfizer Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Novartis AG
  • Bayer AG
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Merck KGaA
  • GSK plc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca
  • AbCellera Biologics Inc.
  • Molecular Depot LLC
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Abbott
  • Biogen
  • Thermo Fisher Scientific, Inc.
  • Cell Signaling Technology, Inc
  • Intas Pharmaceuticals Ltd.
  • Avantor Inc.
  • UCB S.A.
  • Merus N.V.
  • GENEXTGENOMICS.COM
  • Biogenuix

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Source
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Highlights
  • Product Launch
  • Technological Advancements
  • PEST Analysis
  • Regulatory Scenario
  • Mergers and Acquisitions

4. Global Monoclonal Antibody Therapeutics Market, By Source, (US$ Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Human
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Chimeric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Murine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Humanized
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Monoclonal Antibody Therapeutics Market, By Application, 2021 - 2033, (US$ Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Autoimmune Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Hematological Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Infectious Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Monoclonal Antibody Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segments Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Monoclonal Antibody Therapeutics Market, By Region, 2021 - 2033, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2022-2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Pfizer Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Regeneron Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbCellera Biologics Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Molecular Depot LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • DAIICHI SANKYO COMPANY, LIMITED.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biogen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Thermo Fisher Scientific, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Cell Signaling Technology, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Intas Pharmaceuticals Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Avantor, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • UCB S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merus N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GENEXTGENOMICS.COM
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biogenuix
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us